No abstract
upuytren disease is a common fibroproliferative hand disease, with a worldwide prevalence of approximately 8.2%. 1 Although frequently regarded as benign and not requiring prevention, the fixed flexion deformity characterizing Dupuytren disease progression causes significant disability. 2 There are currently no preventative therapies, and surgical management is not without risk. Recurrence is common, and Background: Dupuytren disease is associated with significant comorbidity and mortality, and it has no existing prevention strategies. It is unclear which modifiable risk factors are most amenable for prevention. This study aimed to determine the strength of modifiable risk factors for Dupuytren disease, and to investigate associations with other diseases. Methods: Using UK Biobank data, this case-control study analyzed the association between phenotypic variables and Dupuytren disease through multivariable logistic regression. Exposures assessed were age, sex, body mass index, waist-to-hip ratio, Townsend deprivation index, smoking status, alcohol intake, diabetes mellitus, hypertension, cancer, liver disease, respiratory disease, rheumatoid arthritis, epilepsy, psoriasis, and gout.
Background/Aims To examine the management of fibromyalgia patients referred to secondary care with respect to 2017 European Alliance of Associations for Rheumatology (EULAR) guidelines. Methods Eighty-two patients referred to the Complex Musculoskeletal Clinic in the Rheumatology Department with a resulting diagnosis of fibromyalgia were included in the audit. Data was collected retrospectively via Electronic Patient Records over the study period of December 2017 to March 2020. Variables assessed included patient demographics, clinical presentation at assessment and management. Statistical analyses were conducted using Excel 2019 and the Excel Analysis ToolPak. Results The majority of the patients were female 77/82(94%), and the mean age was 43.2yrs (SD = 12.6). Co-morbidities were common: 31/82 (38%) had a further painful musculoskeletal condition, 40/82 (49%) were obese and 46/82 (56%) had an active mental health problem. Alongside chronic widespread pain, patients reported fatigue 64/82 (78%), waking unrefreshed 69/82 (84%), and cognitive disturbance 31/82 (38%). Compared to a 2014 audit conducted in the same population and department, more patients had received pharmacological treatment (71/82 [87%] vs 34/50 [68%]; z = 2.64, p = 0.008), had received physiotherapy (28/82 [34%] vs 5/50 [10%]; z = 3.0, p = 0.002) and psychological input (16/82 [20%] vs 3/50 [6%]; z = 2.20, p = 0.03) prior to referral to secondary care. At secondary care consultation, all patients received an assessment of their pain and function, and 64/82 (78%) were assessed for psychosocial context. Fifty-three (65%) patients received information in the form of a website recommendation, leaflet or verbal education. After clinician assessment, the majority were referred to a multidisciplinary pain management programme, in a significant increase from 2014 (64/82 [78%] vs 4/50 [8%]; z = 8.04, p < 0.0001). All medication recommendations were made according to 2017 EULAR guidelines. Alongside multidisciplinary pain rehabilitation, patients were referred to physiotherapy 21/82 (26%), physical activity 26/82 (26%), sleep hygiene 9/82 (11%) and psychological 7/82 (9%) treatment options. Conclusion Multidisciplinary treatment and first-line, non-pharmacological approaches have become the standard management approach in secondary care, alongside EULAR compliant pharmacological recommendations. EULAR’s non-pharmacological recommendations of assessing not only pain, but function and psychosocial context occurs for the majority of patients. The limitation of consultation duration likely plays a role in whether psychosocial context is adequately assessed. Providing patients with information about their condition, though occurring for approximately 2/3 of patients, was recognized as an area for improvement. The high rate of co-morbidities combined with the demographics of Fibromyalgia patients emphasizes the importance of early, multimodal management. Follow-up audits are warranted to examine the effects of the COVID-19 pandemic, and the impact of the upcoming 2021 NICE guidance for chronic pain. Disclosure Y. Kang: None. R. Smith: None. A. Soni: Grants/research support; Oxford-UCB Prize Fellowship.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.